Shares of Boston Scientific Corporation (NYSE:BSX) have earned an average recommendation of “Buy” from the twenty-two analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $30.93.

Several equities research analysts have recently commented on the stock. Canaccord Genuity assumed coverage on shares of Boston Scientific Corporation in a research note on Tuesday, October 24th. They issued a “buy” rating and a $36.00 target price on the stock. Zacks Investment Research upgraded shares of Boston Scientific Corporation from a “sell” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Friday, October 20th. Needham & Company LLC restated a “buy” rating and issued a $32.00 target price on shares of Boston Scientific Corporation in a research note on Tuesday, October 3rd. BMO Capital Markets restated a “buy” rating and issued a $30.00 target price on shares of Boston Scientific Corporation in a research note on Friday, October 13th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $34.00 price target on shares of Boston Scientific Corporation in a research report on Monday, October 2nd.

In related news, EVP Supratim Bose sold 347,137 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $29.12, for a total value of $10,108,629.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $26.87, for a total value of $416,485.00. The disclosure for this sale can be found here. In the last three months, insiders sold 508,864 shares of company stock valued at $14,581,669. 0.74% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Swiss National Bank increased its position in Boston Scientific Corporation by 2.9% during the 2nd quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock worth $154,814,000 after buying an additional 156,800 shares during the period. Wells Fargo & Company MN increased its position in shares of Boston Scientific Corporation by 10.5% in the second quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock worth $253,854,000 after purchasing an additional 867,983 shares during the period. Sit Investment Associates Inc. increased its position in shares of Boston Scientific Corporation by 37.8% in the third quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock worth $4,134,000 after purchasing an additional 38,855 shares during the period. Los Angeles Capital Management & Equity Research Inc. increased its position in shares of Boston Scientific Corporation by 35,016.2% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after purchasing an additional 3,033,800 shares during the period. Finally, LS Investment Advisors LLC increased its position in shares of Boston Scientific Corporation by 5.8% in the third quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock worth $1,185,000 after purchasing an additional 2,209 shares during the period. Institutional investors and hedge funds own 90.47% of the company’s stock.

Boston Scientific Corporation (BSX) traded up $0.42 on Friday, reaching $27.86. 7,180,578 shares of the company’s stock were exchanged, compared to its average volume of 5,898,935. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. The stock has a market cap of $38,250.38, a price-to-earnings ratio of 22.83, a P/E/G ratio of 2.15 and a beta of 1.00.

Boston Scientific Corporation (NYSE:BSX) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.31. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the company earned $0.27 EPS. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. analysts predict that Boston Scientific Corporation will post 1.25 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/boston-scientific-corporation-bsx-given-average-rating-of-buy-by-analysts/1680674.html.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.